Nizatidine

For the treatment of the following diseases where reduction of gastric acid is indicated: Duodenal ulcer Benign gastric ulcer Prevention of duodenal or benign gastric ulcer recurrence Gastric oesophageal reflux disease (including erosions, ulcerations and associated heartburn) Gastric and/or duodenal ulcer associated with concomitant use of non-steroidal anti- inflammatory drugs

AXID (nizatidine capsules) is indicated for:  the treatment of conditions where a controlled reduction of gastric acid secretion is required such as for ulcer healing and/or pain relief: acute duodenal ulcer, acute benign gastric ulcer, gastroesophageal reflux disease and prophylactic use in duodenal ulcer.

1 Pediatrics Pediatrics (under 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 2 Geriatrics Geriatrics (over 65 years of age): Evidence from clinical studies and experience do not suggest that use in the geriatric population is associated with differences in safety or effectiveness .

Age alone is not an important factor in determining the disposition of nizati dine; however elderly patients may have reduced renal function. 3 CLINICAL PHARMACOLOGY, Pharmacokinetics, Elimination.